Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143622 | 0.95 | CYP2C8 (0.59) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL120370 | 0.91 | CYP2C8 (0.56) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2141774 | 0.88 | CYP2C8 (0.59) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2142192 | 0.87 | CYP2C8 (0.62) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL120828 | 0.87 | CYP2C8 (0.77) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL1918342 | 0.86 | CYP2C8 (0.56) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2141434 | 0.86 | CYP2C8 (0.64) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2142485 | 0.86 | CYP2C8 (0.62) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2141021 | 0.85 | CYP2C8 (0.75) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2141111 | 0.85 | CYP2C8 (0.62) | CYP2C8CYP3A4KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545051-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-04-19 | — | — | EP | claimed |
| EP-2545051-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | claimed |
| US-8354410-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | claimed |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | claimed |
| WO-2011112769-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | claimed |
| EP-2545051-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2545051-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2545051-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8354410-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354410-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354410-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| WO-2011112769-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112769-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C8 85/4885CYP3A4 299/4885KCNH2 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.